These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11702057)

  • 1. Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan.
    Chen CH; Hung CC; Wei FC; Koong FJ
    Psychiatr Genet; 2001 Sep; 11(3):153-5. PubMed ID: 11702057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism and Parkinson's disease in Taiwan: study of debrisoquine 4-hydroxylase (CYP2D6).
    Lo HS; Chen CH; Hogan EL; Kao KP; Wang V; Yan SH
    J Neurol Sci; 1998 Jun; 158(1):38-42. PubMed ID: 9667775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.
    Jönsson EG; Dahl ML; Roh HK; Jerling M; Sedvall GC
    Psychiatr Genet; 1998; 8(1):25-8. PubMed ID: 9564684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
    Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
    Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
    Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.
    Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC
    Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
    Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
    Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
    Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
    Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
    Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians.
    Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Gesteira A; Barros F; Carracedo A; Hutz MH
    Pharmacogenomics; 2009 Sep; 10(9):1457-66. PubMed ID: 19761369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.
    Masimirembwa C; Persson I; Bertilsson L; Hasler J; Ingelman-Sundberg M
    Br J Clin Pharmacol; 1996 Dec; 42(6):713-9. PubMed ID: 8971426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.
    Kawanishi C; Hanihara T; Maruyama Y; Matsumura T; Onishi H; Inoue K; Sugiyama N; Suzuki K; Yamada Y; Kosaka K
    Psychiatr Genet; 1997; 7(3):127-9. PubMed ID: 9323326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses.
    Varela N; Quiñones LA; Stojanova J; Garay J; Cáceres D; Cespedes S; Sasso J; Miranda C
    Pharmacol Res; 2015 Nov; 101():124-9. PubMed ID: 26211952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.
    Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K
    Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
    Singh M; Khanna VK; Shukla R; Parmar D
    Dis Markers; 2010; 28(2):87-93. PubMed ID: 20364044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
    Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.
    Leathart JB; London SJ; Steward A; Adams JD; Idle JR; Daly AK
    Pharmacogenetics; 1998 Dec; 8(6):529-41. PubMed ID: 9918137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
    Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
    Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese.
    Ji L; Pan S; Marti-Jaun J; Hänseler E; Rentsch K; Hersberger M
    Clin Chem; 2002 Jul; 48(7):983-8. PubMed ID: 12089164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.